Appropriate use of the anti-methicillin-resistant Staphylococcus aureus agents in retrospective study

Yasutaka Nakamura, Iichirou Yokoyama, Noriko Hashimoto, Atsushi Hasegawa, Hiromitsu Nakasa, Hiroyoshi Nakamura, Masaharu Watanabe, Fumio Nomura, Akira Watanabe, Hidetoshi Igari, Takeyuki Sato, Kazuyoshi Nakazawa, Noritaka Ariyoshi, Mitsukazu Kitada

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The track records of the use of anti-methicillin-resistant Staphylococcus aureus agents (anti-MRSA agents) in a 5-year period (2001.4-2006.3) were collected, and cases in which anti-MRSA agents were used for >4 days were selected. In each case, the results of laboratory data and bacterial examination before and after administering the anti-MRSA agents were investigated retrospectively. In addition, it was also investigated in each case whether therapeutic drug monitoring (TDM) was carried out. It was observed that the number of patients treated with anti-MRSA agents and the total dose of anti-MRSA agents used tended to increase over time, except for arbekacin sulfate. It was, however, shown that treatment with anti-MRSA agents resulted in significant decreases in body temperature, C-reactive protein, and white blood cell counts. Bacterial examination was conducted in 75.6% of the patients treated with anti-MRSA agents, with MRSA being detected in 72.4% of the cases examined. On the other hand, TDM was also conducted in 60% of the cases, but this was at a lower percentage than that of the other examinations. Quantitative bacterial examination after treatment with anti-MRSA agents indicates that TDM can be considered important for the appropriate use of anti-MRSA agents.

Original languageEnglish
Pages (from-to)1073-1079
Number of pages7
JournalYakugaku Zasshi
Volume128
Issue number7
DOIs
Publication statusPublished - Jul 2008
Externally publishedYes

Fingerprint

Methicillin-Resistant Staphylococcus aureus
Retrospective Studies
Drug Monitoring
Body Temperature
Leukocyte Count
C-Reactive Protein
Therapeutics

Keywords

  • Anti-methicillin-resistant staphylococcus aureus agents (anti-MRSA agents)
  • Arbekacin sulfate (ABK)
  • Teicoplanin (TEIC)
  • Therapeutic drug monitoring (TDM)
  • Vancomycin hydrochloride (VCM)

ASJC Scopus subject areas

  • Molecular Medicine

Cite this

Nakamura, Y., Yokoyama, I., Hashimoto, N., Hasegawa, A., Nakasa, H., Nakamura, H., ... Kitada, M. (2008). Appropriate use of the anti-methicillin-resistant Staphylococcus aureus agents in retrospective study. Yakugaku Zasshi, 128(7), 1073-1079. https://doi.org/10.1248/yakushi.128.1073

Appropriate use of the anti-methicillin-resistant Staphylococcus aureus agents in retrospective study. / Nakamura, Yasutaka; Yokoyama, Iichirou; Hashimoto, Noriko; Hasegawa, Atsushi; Nakasa, Hiromitsu; Nakamura, Hiroyoshi; Watanabe, Masaharu; Nomura, Fumio; Watanabe, Akira; Igari, Hidetoshi; Sato, Takeyuki; Nakazawa, Kazuyoshi; Ariyoshi, Noritaka; Kitada, Mitsukazu.

In: Yakugaku Zasshi, Vol. 128, No. 7, 07.2008, p. 1073-1079.

Research output: Contribution to journalArticle

Nakamura, Y, Yokoyama, I, Hashimoto, N, Hasegawa, A, Nakasa, H, Nakamura, H, Watanabe, M, Nomura, F, Watanabe, A, Igari, H, Sato, T, Nakazawa, K, Ariyoshi, N & Kitada, M 2008, 'Appropriate use of the anti-methicillin-resistant Staphylococcus aureus agents in retrospective study', Yakugaku Zasshi, vol. 128, no. 7, pp. 1073-1079. https://doi.org/10.1248/yakushi.128.1073
Nakamura Y, Yokoyama I, Hashimoto N, Hasegawa A, Nakasa H, Nakamura H et al. Appropriate use of the anti-methicillin-resistant Staphylococcus aureus agents in retrospective study. Yakugaku Zasshi. 2008 Jul;128(7):1073-1079. https://doi.org/10.1248/yakushi.128.1073
Nakamura, Yasutaka ; Yokoyama, Iichirou ; Hashimoto, Noriko ; Hasegawa, Atsushi ; Nakasa, Hiromitsu ; Nakamura, Hiroyoshi ; Watanabe, Masaharu ; Nomura, Fumio ; Watanabe, Akira ; Igari, Hidetoshi ; Sato, Takeyuki ; Nakazawa, Kazuyoshi ; Ariyoshi, Noritaka ; Kitada, Mitsukazu. / Appropriate use of the anti-methicillin-resistant Staphylococcus aureus agents in retrospective study. In: Yakugaku Zasshi. 2008 ; Vol. 128, No. 7. pp. 1073-1079.
@article{e8ab1e8e2c6344fca2fdb320f41c60bf,
title = "Appropriate use of the anti-methicillin-resistant Staphylococcus aureus agents in retrospective study",
abstract = "The track records of the use of anti-methicillin-resistant Staphylococcus aureus agents (anti-MRSA agents) in a 5-year period (2001.4-2006.3) were collected, and cases in which anti-MRSA agents were used for >4 days were selected. In each case, the results of laboratory data and bacterial examination before and after administering the anti-MRSA agents were investigated retrospectively. In addition, it was also investigated in each case whether therapeutic drug monitoring (TDM) was carried out. It was observed that the number of patients treated with anti-MRSA agents and the total dose of anti-MRSA agents used tended to increase over time, except for arbekacin sulfate. It was, however, shown that treatment with anti-MRSA agents resulted in significant decreases in body temperature, C-reactive protein, and white blood cell counts. Bacterial examination was conducted in 75.6{\%} of the patients treated with anti-MRSA agents, with MRSA being detected in 72.4{\%} of the cases examined. On the other hand, TDM was also conducted in 60{\%} of the cases, but this was at a lower percentage than that of the other examinations. Quantitative bacterial examination after treatment with anti-MRSA agents indicates that TDM can be considered important for the appropriate use of anti-MRSA agents.",
keywords = "Anti-methicillin-resistant staphylococcus aureus agents (anti-MRSA agents), Arbekacin sulfate (ABK), Teicoplanin (TEIC), Therapeutic drug monitoring (TDM), Vancomycin hydrochloride (VCM)",
author = "Yasutaka Nakamura and Iichirou Yokoyama and Noriko Hashimoto and Atsushi Hasegawa and Hiromitsu Nakasa and Hiroyoshi Nakamura and Masaharu Watanabe and Fumio Nomura and Akira Watanabe and Hidetoshi Igari and Takeyuki Sato and Kazuyoshi Nakazawa and Noritaka Ariyoshi and Mitsukazu Kitada",
year = "2008",
month = "7",
doi = "10.1248/yakushi.128.1073",
language = "English",
volume = "128",
pages = "1073--1079",
journal = "Yakugaku Zasshi",
issn = "0031-6903",
publisher = "Pharmaceutical Society of Japan",
number = "7",

}

TY - JOUR

T1 - Appropriate use of the anti-methicillin-resistant Staphylococcus aureus agents in retrospective study

AU - Nakamura, Yasutaka

AU - Yokoyama, Iichirou

AU - Hashimoto, Noriko

AU - Hasegawa, Atsushi

AU - Nakasa, Hiromitsu

AU - Nakamura, Hiroyoshi

AU - Watanabe, Masaharu

AU - Nomura, Fumio

AU - Watanabe, Akira

AU - Igari, Hidetoshi

AU - Sato, Takeyuki

AU - Nakazawa, Kazuyoshi

AU - Ariyoshi, Noritaka

AU - Kitada, Mitsukazu

PY - 2008/7

Y1 - 2008/7

N2 - The track records of the use of anti-methicillin-resistant Staphylococcus aureus agents (anti-MRSA agents) in a 5-year period (2001.4-2006.3) were collected, and cases in which anti-MRSA agents were used for >4 days were selected. In each case, the results of laboratory data and bacterial examination before and after administering the anti-MRSA agents were investigated retrospectively. In addition, it was also investigated in each case whether therapeutic drug monitoring (TDM) was carried out. It was observed that the number of patients treated with anti-MRSA agents and the total dose of anti-MRSA agents used tended to increase over time, except for arbekacin sulfate. It was, however, shown that treatment with anti-MRSA agents resulted in significant decreases in body temperature, C-reactive protein, and white blood cell counts. Bacterial examination was conducted in 75.6% of the patients treated with anti-MRSA agents, with MRSA being detected in 72.4% of the cases examined. On the other hand, TDM was also conducted in 60% of the cases, but this was at a lower percentage than that of the other examinations. Quantitative bacterial examination after treatment with anti-MRSA agents indicates that TDM can be considered important for the appropriate use of anti-MRSA agents.

AB - The track records of the use of anti-methicillin-resistant Staphylococcus aureus agents (anti-MRSA agents) in a 5-year period (2001.4-2006.3) were collected, and cases in which anti-MRSA agents were used for >4 days were selected. In each case, the results of laboratory data and bacterial examination before and after administering the anti-MRSA agents were investigated retrospectively. In addition, it was also investigated in each case whether therapeutic drug monitoring (TDM) was carried out. It was observed that the number of patients treated with anti-MRSA agents and the total dose of anti-MRSA agents used tended to increase over time, except for arbekacin sulfate. It was, however, shown that treatment with anti-MRSA agents resulted in significant decreases in body temperature, C-reactive protein, and white blood cell counts. Bacterial examination was conducted in 75.6% of the patients treated with anti-MRSA agents, with MRSA being detected in 72.4% of the cases examined. On the other hand, TDM was also conducted in 60% of the cases, but this was at a lower percentage than that of the other examinations. Quantitative bacterial examination after treatment with anti-MRSA agents indicates that TDM can be considered important for the appropriate use of anti-MRSA agents.

KW - Anti-methicillin-resistant staphylococcus aureus agents (anti-MRSA agents)

KW - Arbekacin sulfate (ABK)

KW - Teicoplanin (TEIC)

KW - Therapeutic drug monitoring (TDM)

KW - Vancomycin hydrochloride (VCM)

UR - http://www.scopus.com/inward/record.url?scp=46849111411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46849111411&partnerID=8YFLogxK

U2 - 10.1248/yakushi.128.1073

DO - 10.1248/yakushi.128.1073

M3 - Article

C2 - 18591876

AN - SCOPUS:46849111411

VL - 128

SP - 1073

EP - 1079

JO - Yakugaku Zasshi

JF - Yakugaku Zasshi

SN - 0031-6903

IS - 7

ER -